In 2023, our Millburn, New Jersey, site became the first Novartis manufacturing location in the US to produce radioligand therapy (RLT), a type of precision treatment that pairs a tumor-targeting molecule (ligand) with a therapeutic radioisotope, allowing radiation to be delivered directly to the tumor while minimizing harm to surrounding healthy tissue. Since then, we have expanded on-site production capabilities to meet growing demand.
Key Facts About the Site
2018
1st
27.5K
across three buildings
Featured Stories
Designing for the Future: The Next Era of Biomedical Research in San Diego
Thierry Diagana, California Sites Head at Novartis, shares the vision for a new research hub that will power future drug discovery.
Innovating for America: How Our New RLT Manufacturing Site Can Help Ensure Continued On Time Delivery to Patients Now and in Future
As Novartis expands its manufacturing capabilities, our new Carlsbad facility will help deliver time-sensitive cancer treatments to patients, meeting future demand.
How This Former Army Officer Helps Deliver Cancer Treatments to Patients
Radioligand therapies harness the power of radioisotopes to target cancer with precision. For Matt Baca, delivering a dose in a three-to-five-day window is all in a day’s work.
